February 27, 2020 / 3:06 PM / a month ago

BRIEF-Herantis Pharma H2 Loss For The Period Widens To EUR 4.7 Mln

Feb 27 (Reuters) - Herantis Pharma Oyj:

* GUIDANCE FOR 2020: CO DOES NOT EXPECT MATERIAL REVENUES IN 2020

* MAIN OBJECTIVES FOR 2020 ARE TO PRESENT INITIAL RESULTS OF PHASE 1-2 CLINICAL STUDY OF CDNF IN Q1, AND TWELVE-MONTH FOLLOW-UP RESULTS IN Q3

* H2 LOSS FOR THE PERIOD EUR 4.7 MILLION VERSUS LOSS EUR 2.4 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below